Fig. 4.

a High MHC-II expression score (> median) is more significantly correlated with low overall neoantigen immunogenicity score (p = 0.0007) than mutation burden and neoantigen burden, while cytolytic activity did not correlate with mutation burden, neoantigen burden, or overall neoantigen immunogenicity score in lung adenocarcinoma. b Kaplan-Meier estimates of overall survival according to mutation burden, tumor neoantigen burden (TNB), overall tumor neoantigen immunogenicity score (TNS), cytolytic activity, and MHC-II expression. The median of each value was selected as the cutoff for high vs low separation in all biomarkers. c Univariate and multivariate Cox regression survival analyses of TCGA LUAD data on different single biomarkers and all. TNB, tumor neoantigen burden; TNS, overall tumor neoantigen immunogenicity score; HR, hazard ratio; CI, confidence interval